Addressing this issue, a rapid DPT with CM has recently been developed, demonstrating both efficacy and safety confirmed37-39.
The main objective in our study was to assess the applicability of administering ICM at rapid speed rater in a larger population, including patients with anaphylaxis. Additionally, a statistical analysis was performed to characterize our population based on diverse clinical data.
MATERIAL AND METHODS
Patients aged 18 years and older with a history of immediate or delayed HSR to ICM were included in the study. These patients were referred from both Primary Care and Specialized Medical Units. Clinical data were recorded using an adapted version of the ENDA drug allergy questionnaire40. Collected data included diverse demographics and co-morbidities, information about previous radiological procedures, the ICM administered, descriptions of the HSR to ICM, required treatments, and the time elapsed until initiation of the allergy study.
To differentiate between immediate and delayed reactions, we used a threshold of 1 hour, considering that intravenous administration of ICM minimized the potential bias of digestive drug absorption. Thus, a HSR was classified as immediate if onset occurred within the first hour after ICM administration, and as delayed if onset occurred more than 1 hour later.
We used the scoring system proposed by Brown41 to assess the severity of immediate reactions and the one proposed by Brown for delayed-type reactions19
This prospective study was approved by the regional institutional review board under approval number 3396, and written informed consent was obtained from each patient before testing. Diagnostic procedures followed a flowchart like one previously reported37. ST and DPT were performed using a panel of ICM including Iohexol (Ommipaque© 300 mg/ml, GE Healthcare, Spain), Ioversol (Optiray© 300 mg/ml, Guerbet, Spain), Iodixanol (Visipaque© 270 mg/ml, GE Healthcare, Spain), and Iobitridol (Xenetix© 300 mg/ml, Guerbet, Spain).